Empowering AI assisted clinical drug development: tactics to address data bias, the digital divide and missing patient populations through AI and digital solutions - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Enhancing Clinical Drug Development with AI: Strategies to Mitigate Data Bias, Bridge the Digital Divide, and Include Underrepresented Patient Groups

  • By

  • Dimitris Papanicolaou

  • Sotirios Perdikeas

  • Graham B. Jones

  • August 12, 2026

Share

  • 1

    AI methodologies can accelerate clinical trials by identifying patients likely to respond positively to specific medications.

  • 2

    Datasets used for predictive analyses must be representative of diverse populations to leverage the advantages of AI in precision medicine.

  • 3

    Biases in datasets, such as underrepresentation of certain racial and ethnic groups, limit the effectiveness of predictive models.

  • 4

    Patient-generated data can be biased due to language disparities and unequal access to healthcare and digital resources.

  • 5

    Enhancing dataset heterogeneity is essential to mitigate biases and improve the generalizability of AI-driven clinical trial outcomes.

Original Source(s)

Empowering AI assisted clinical drug development: tactics to address data bias, the digital divide and missing patient populations through AI and digital solutions

  • by Dimitris Papanicolaou, Sotirios Perdikeas, Graham B. Jones

  • August 12, 2026

Related Content

Comment to: Comparison of open and laparoscopic inguinal hernia repair in the elderly patients: a randomized controlled trial

Reliability and readability of Artificial Intelligence generated information on acute cholecystitis: A comparative analysis

Tree Canopy Gains Linked to Lower Mortality

The association was most pronounced in Chicago’s hottest neighborhoods, where canopy losses were linked to higher predicted mortality.